Table 1. Baseline characteristics.
| Patient characteristics | All STK11-mutated (n=41) | STK11/KRAS co-mutated (n=22) | STK11-mutated/KRAS wt (n=19) |
|---|---|---|---|
| Age at diagnosis (years), median (range) | 65.4 (47.4 to 87.0) | 64.3 (47.4 to 79.8) | 67.6 (55.4 to 87.0) |
| Sex, n [%] | |||
| Male | 24 [59] | 13 [59] | 11 [58] |
| Female | 17 [41] | 9 [41] | 8 [42] |
| Race, n [%] | |||
| African American | 1 [2] | 0 | 1 [5] |
| White | 36 [88] | 21 [95] | 15 [79] |
| Hispanic | 2 [5] | 0 | 2 [11] |
| Asian | 2 [5] | 1 [5] | 1 [5] |
| Smoking history | |||
| Current smoker | 5 [12] | 3 [14] | 2 [11] |
| Former smoker | 34 [83] | 18 [82] | 16 [84] |
| Never smoker | 2 [5] | 1 [4] | 1 [5] |
| Pack-years in smokers, mean (SD) | 36.9 (21.1) | 35.8 (18.3) | 38.3 (24.4) |
| ECOG PS at diagnosis | |||
| 0–1 | 32 [78] | 17 [77] | 15 [79] |
| ≥2 | 9 [22] | 5 [23] | 4 [21] |
| Stage at diagnosis, n [%] | |||
| I–II | 12 [29] | 7 [32] | 5 [26] |
| III | 7 [17] | 4 [18] | 3 [16] |
| IV | 22 [54] | 11 [50] | 11 [58] |
| Stage IV at any time, n [%] | 35 [85] | 18 [82] | 17 [89] |
| Brain metastases, n [%] | 14 [34] | 7 [32] | 7 [37] |
| Histology, n [%] | |||
| Adenocarcinoma | 35 [85] | 20 [90] | 15 [79] |
| Squamous | 4 [10] | 1 [5] | 3 [16] |
| NSCLC, other | 2 [5] | 1 [5] | 1 [5] |
| PD-L1 status | |||
| N with PD-L1 known | 13 | 5 | 8 |
| ≥50% | 3 [23] | 2 [40] | 1 [13] |
| 1–50% | 4 [31] | 1 [20] | 3 [37] |
| ≤1% | 6 [46] | 2 [20] | 4 [50] |
| TMB, mutations/Mb | |||
| N with TMB available | 39 | 22 | 17 |
| Median TMB, range | 8 (1 to 59.2) | 6.5 (1 to 21.7) | 9 (3.6 to 59.2) |
| TMB ≥10, n [%] | 15 [38] | 7 [32] | 8 [47] |
SD, standard deviation; ECOG PS, Eastern Cooperative Oncology group scale of performance status; NSCLC, non-small cell lung cancer; TMB, tumor mutation burden.